ATE557017T1 - Pyrrolidinonglucokinase-aktivatoren - Google Patents

Pyrrolidinonglucokinase-aktivatoren

Info

Publication number
ATE557017T1
ATE557017T1 AT09732665T AT09732665T ATE557017T1 AT E557017 T1 ATE557017 T1 AT E557017T1 AT 09732665 T AT09732665 T AT 09732665T AT 09732665 T AT09732665 T AT 09732665T AT E557017 T1 ATE557017 T1 AT E557017T1
Authority
AT
Austria
Prior art keywords
pyrrolidinone
glucokinase activators
glucokinase
activators
pyrrolidinone glucokinase
Prior art date
Application number
AT09732665T
Other languages
English (en)
Inventor
Steven Berthel
John Brinkman
Stuart Hayden
Nancy-Ellen Haynes
Robert Kester
Lee Mcdermott
Yimin Qian
Ramakanth Sarabu
Nathan Scott
Jefferson Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE557017T1 publication Critical patent/ATE557017T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT09732665T 2008-04-16 2009-04-06 Pyrrolidinonglucokinase-aktivatoren ATE557017T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4537008P 2008-04-16 2008-04-16
US14576109P 2009-01-20 2009-01-20
PCT/EP2009/054067 WO2009127546A1 (en) 2008-04-16 2009-04-06 Pyrrolidinone glucokinase activators

Publications (1)

Publication Number Publication Date
ATE557017T1 true ATE557017T1 (de) 2012-05-15

Family

ID=40785354

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09732665T ATE557017T1 (de) 2008-04-16 2009-04-06 Pyrrolidinonglucokinase-aktivatoren

Country Status (25)

Country Link
US (1) US7741327B2 (de)
EP (1) EP2274297B1 (de)
JP (1) JP5518838B2 (de)
KR (1) KR101259249B1 (de)
CN (1) CN102007118B (de)
AR (1) AR071474A1 (de)
AT (1) ATE557017T1 (de)
AU (1) AU2009237794B2 (de)
BR (1) BRPI0911035B8 (de)
CA (1) CA2720524C (de)
CL (1) CL2009000889A1 (de)
CY (1) CY1112921T1 (de)
DK (1) DK2274297T3 (de)
ES (1) ES2386192T3 (de)
HR (1) HRP20120589T1 (de)
IL (1) IL207503A (de)
MX (1) MX2010011226A (de)
PE (1) PE20091842A1 (de)
PL (1) PL2274297T3 (de)
PT (1) PT2274297E (de)
RU (1) RU2010146384A (de)
SI (1) SI2274297T1 (de)
TW (1) TW200944519A (de)
WO (1) WO2009127546A1 (de)
ZA (1) ZA201006159B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8178689B2 (en) * 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
US20120142705A1 (en) * 2010-12-06 2012-06-07 Robert Francis Kester Isatin and oxindole compounds
US8470866B2 (en) * 2011-05-03 2013-06-25 Hoffmann-La Roche Inc. Isoindolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PL2938609T3 (pl) * 2012-12-25 2017-08-31 Hua Medicine Sposób wytwarzania 1-([1,3]dioksolan-4-ylometylo)-1h-pirazol-3- iloaminy
JP7072557B2 (ja) 2016-07-22 2022-05-20 ブリストル-マイヤーズ スクイブ カンパニー グルコキナーゼ活性化剤およびその使用方法
EP3556354B1 (de) * 2016-12-15 2025-05-21 Hua Medicine (Shanghai) Ltd. Orale herstellung eines glucokinaseaktivators und herstellungsverfahren dafür
CN110337436A (zh) 2016-12-22 2019-10-15 拜耳作物科学股份公司 取代的1,2,4-噻二唑基吡咯酮和1,2,4-噻二唑基乙内酰脲及其盐及其作为除草剂的用途
BR112019012584A2 (pt) 2016-12-22 2019-11-19 Bayer Ag heteroarilpirrolonas substituídas e sais das mesmas e uso das mesmas como substâncias ativas herbicidas
JP2021507894A (ja) 2017-12-19 2021-02-25 バイエル、アクチエンゲゼルシャフトBayer Aktiengesellschaft 置換されたn−ヘテロシクリル−およびn−ヘテロアリール−テトラヒドロピリミジノンならびにその塩、ならびに除草活性物質としてのその使用
AU2019278015B2 (en) * 2018-05-31 2024-10-03 Hua Medicine (Shanghai) Ltd. Pharmaceutical combination, composition, and combination formulation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof
CN113493442B (zh) * 2020-04-03 2024-11-08 天津药物研究院有限公司 作为葡萄糖激酶活化剂的吡咯烷酮衍生物及其制备方法和用途
US11813274B2 (en) 2020-04-22 2023-11-14 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
AU2020443475A1 (en) * 2020-04-22 2022-11-17 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor
IL300893A (en) * 2020-08-24 2023-04-01 Hua Medicine Shanghai Ltd Preparation of modified acrylate compounds
TWI817307B (zh) * 2021-01-04 2023-10-01 大陸商華領醫藥技術(上海)有限公司 多扎格列艾汀(dorzagliatin)和胰高血糖素樣肽-1類似物的藥物組成物
CN113527265B9 (zh) * 2021-02-02 2022-07-19 湖南南新制药股份有限公司 一种氘代吡咯烷酮衍生物、药物组合物及其用途
CN113750100B (zh) * 2021-08-31 2022-12-30 海南中济医药科技有限公司 一种含有多扎格列艾汀与西格列汀的药物组合物及其制备方法
AR127064A1 (es) 2021-09-15 2023-12-13 Hua Medicine Shanghai Ltd Prodroga de derivados de pirrolidona como activador de glucoquinasa
EP4516778A4 (de) 2022-04-25 2026-04-29 Nippon Shinyaku Co Ltd Verbindung als ddr1-kinasehemmer und medikament
AR132113A1 (es) * 2023-03-13 2025-05-28 Hua Medicine Shanghai Ltd Forma sólida de derivados de pirrolidona como activador de glucoquinasa
TW202541799A (zh) 2023-12-14 2025-11-01 美商華領醫藥美國有限公司 包含葡萄糖激酶激活劑之醫藥調配物及其用途
CN118812408A (zh) * 2024-09-18 2024-10-22 潍坊市海欣药业有限公司 一种多格列艾汀关键中间体的合成方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE842346C (de) 1950-10-14 1952-06-26 Joachim Dipl-Chem Dr Goerdeler Verfahren zur Darstellung von 5-Amino-1, 2, 4-thiodiazolen
AU3442484A (en) 1983-10-18 1985-04-26 E.I. Du Pont De Nemours And Company 8-substituted pyrazolopentathiepins
JPS6284064A (ja) 1985-10-09 1987-04-17 Shionogi & Co Ltd 3−パ−フルオロアルキル−5−ヒドロキシイソオキサゾ−ル類
CH668422A5 (de) 1986-06-26 1988-12-30 Lonza Ag 4-benzyloxy-3-pyrrolin-2-on, dessen herstellung und verwendung zur synthese von tetramsaeure.
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
IL116507A (en) 1991-11-13 1997-08-14 Schering Ag Pyrazole derivatives
US5498190A (en) 1994-06-27 1996-03-12 Handsontoys, Inc. Flexible foam construction toy and method of manufacturing same
JPH08151386A (ja) 1994-09-27 1996-06-11 Takeda Chem Ind Ltd 複素環エチルチオセフェム化合物、その製造法および抗菌組成物
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
CA2326763A1 (en) 1998-04-30 1999-11-11 Theodore O. Johnson, Jr. Antipicornaviral compounds and compositions, their pharmaceutical uses, and methods for their synthesis
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
RU2242469C2 (ru) 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
PL350669A1 (en) 1999-03-29 2003-01-27 Hoffmann La Roche Glucokinase activators
AU777735B2 (en) 1999-07-15 2004-10-28 Pharmacopeia, Inc. Bradykinin B1 receptor antagonists
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
MXPA02010745A (es) 2000-05-03 2003-03-10 Hoffmann La Roche Activadores de glucocinasa heteroaromaticos de alquinil-fenilo.
DK1282611T3 (da) 2000-05-08 2005-02-14 Hoffmann La Roche Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
WO2001085707A1 (en) 2000-05-08 2001-11-15 F. Hoffmann-La Roche Ag Para-amine substituted phenylamide glucokinase activators
DE60117059T2 (de) 2000-12-06 2006-10-26 F. Hoffmann-La Roche Ag Kondensierte heteroaromatische glucokinaseaktivatoren
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1501815B1 (de) 2002-04-26 2006-11-22 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
WO2004033462A2 (en) 2002-10-09 2004-04-22 The Board Of Trustees Of The University Of Illinois METHOD OF PREPARING (3R, 3aS, 6aR) -3- HYDROXYHEXAHYDROFURO [2, 3-b] FURAN AND RELATED COMPOUNDS
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
US7262196B2 (en) 2003-02-11 2007-08-28 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
US7432287B2 (en) 2003-02-26 2008-10-07 Banyu Pharmeceutical Co., Ltd. Heteroarylcarbamoylbenzene derivative
EP1682524A1 (de) 2003-10-24 2006-07-26 Aventis Pharmaceuticals, Inc. Neue keto-oxadiazolderivate als cathepsininhibitoren
MXPA06004647A (es) 2003-10-27 2006-06-27 Merck & Co Inc Sal antagonista de ccr-2.
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
KR20070007104A (ko) 2004-02-18 2007-01-12 아스트라제네카 아베 화합물
BRPI0507746A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
US7687502B2 (en) 2004-03-23 2010-03-30 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
BRPI0509573A (pt) 2004-04-02 2007-09-25 Novartis Ag derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2
MXPA06012008A (es) 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
KR100890695B1 (ko) 2004-08-12 2009-03-26 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의그의 용도
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
GB0418046D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
GB0423044D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
EP1824835A1 (de) 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatische glucokinaseaktivatoren
WO2006064286A1 (en) 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
WO2006094770A2 (en) 2005-03-08 2006-09-14 Ludwig-Maximilians-Universitaet Muenchen Apparatus and method for the final processing of a forming tool for a sheet-metal body part
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
JP2009500377A (ja) 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー/エス ジシクロアルキルウレア型グルコキナーゼ活性化剤
KR101346902B1 (ko) 2005-07-09 2014-01-02 아스트라제네카 아베 당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체
JP2009500442A (ja) 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ 2型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての2−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
EP2027113A1 (de) 2005-07-09 2009-02-25 AstraZeneca AB Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
JP4033409B1 (ja) 2005-07-11 2008-01-16 田辺三菱製薬株式会社 オキシム誘導体及びその製法
EP1904467B1 (de) 2005-07-14 2013-05-01 Novo Nordisk A/S Harnstoff-Glucokinase-Aktivatoren
JP2009504621A (ja) 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
WO2007026761A1 (ja) 2005-08-31 2007-03-08 Astellas Pharma Inc. チアゾール誘導体
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
CN101316836A (zh) 2005-11-01 2008-12-03 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的二氢异吲哚酮类
WO2007051846A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007051845A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
TWI411607B (zh) 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc 天門冬胺酸蛋白酶抑制劑
EP1948614A2 (de) 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinaseaktivatoren
CN101437512A (zh) 2006-01-27 2009-05-20 阿雷生物药品公司 葡萄糖激酶活化剂
EP2001875A2 (de) 2006-03-08 2008-12-17 Takeda San Diego, Inc. Glucokinase-aktivatoren
RU2457207C2 (ru) 2006-03-24 2012-07-27 Эррэй Биофарма Инк. Активаторы глюкокиназы
WO2007115968A2 (en) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
EP2010520B1 (de) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclische amide zur prävention und behandlung von durch glucokinase-vermittelten krankheiten
WO2007125103A2 (en) 2006-04-28 2007-11-08 Transtech Pharma, Inc. Benzamide glucokinase activators
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
KR20090025358A (ko) 2006-07-24 2009-03-10 에프. 호프만-라 로슈 아게 글루코키나제 활성화제로서의 피라졸
KR20090034395A (ko) * 2006-07-26 2009-04-07 노파르티스 아게 운데카프레닐 피로포스페이트 합성효소의 억제제
JP5248477B2 (ja) 2007-03-07 2013-07-31 杏林製薬株式会社 グルコキナーゼ活性化物質
US20100222326A1 (en) 2007-04-27 2010-09-02 Ucb Pharma, S.A. New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders
CN101121688A (zh) 2007-09-14 2008-02-13 南开大学 合成奥拉西坦的改进方法

Also Published As

Publication number Publication date
CA2720524C (en) 2016-07-12
BRPI0911035A2 (pt) 2019-07-16
AU2009237794B2 (en) 2014-07-10
AR071474A1 (es) 2010-06-23
HRP20120589T1 (hr) 2012-08-31
JP5518838B2 (ja) 2014-06-11
KR20100123912A (ko) 2010-11-25
CY1112921T1 (el) 2016-04-13
EP2274297B1 (de) 2012-05-09
JP2011517692A (ja) 2011-06-16
US7741327B2 (en) 2010-06-22
PT2274297E (pt) 2012-06-20
WO2009127546A1 (en) 2009-10-22
PL2274297T3 (pl) 2012-10-31
SI2274297T1 (sl) 2012-08-31
IL207503A (en) 2014-03-31
PE20091842A1 (es) 2009-12-04
CL2009000889A1 (es) 2010-07-19
ZA201006159B (en) 2011-05-25
CN102007118B (zh) 2014-12-31
MX2010011226A (es) 2010-11-01
ES2386192T3 (es) 2012-08-13
DK2274297T3 (da) 2012-07-16
CA2720524A1 (en) 2009-10-22
RU2010146384A (ru) 2012-05-27
EP2274297A1 (de) 2011-01-19
US20090264445A1 (en) 2009-10-22
CN102007118A (zh) 2011-04-06
IL207503A0 (en) 2010-12-30
KR101259249B1 (ko) 2013-04-30
TW200944519A (en) 2009-11-01
BRPI0911035B8 (pt) 2021-05-25
AU2009237794A1 (en) 2009-10-22
BRPI0911035B1 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
ATE557017T1 (de) Pyrrolidinonglucokinase-aktivatoren
BRPI0912802A2 (pt) ativadores de glicoquinase
NO2015017I1 (no) Apremilast
BRPI0815557A2 (pt) Atividaores de glicocinase
IL207311A0 (en) Glucokinase activators
EP2244670A4 (de) Interspinöses abstandsglied
DK2080901T3 (da) Vindmølle-vindmålings-kompensation
DK2318390T3 (da) Pyrrolforbindelser
PT2231689T (pt) Novos nucleósidos 7-deazapurina citostáticos
BRPI0907755A2 (pt) Artigo multimarcas
BRPI0914649A2 (pt) Piprazolo-quinazolinas
BRPI0923497A2 (pt) derivados de piridazinona
EP2116533A4 (de) Glucokinase-aktivator
BRPI0906705A2 (pt) Composto heterocíclicos
DK2280962T5 (da) Pyridazinonderivater
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
EP2277678A4 (de) Aussenbauteil
HRP20150932T1 (xx) Heterocikliäśki spojevi
EP2339366A4 (de) Gerät zur optischen entfernungsmessung
DK2379722T3 (da) Ekspressionsvektor
DK2257164T3 (da) Herbicid-kombinationer indeholdende diflufenican
BRPI0920924A2 (pt) pirrolidinas
BRPI0911641A2 (pt) unidade estrutural
DE502008003019D1 (de) Einschraubverschraubung
ES1067763Y (es) Dendrometro